Literature DB >> 22020092

Induction of angiopoietin-2 after spinal cord injury.

J C Durham-Lee1, Y Wu, V U L Mokkapati, A A Paulucci-Holthauzen, O Nesic.   

Abstract

Angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) have opposing effects on blood vessels, with Ang-2 being mainly induced during the endothelial barrier breakdown. It is known that spinal cord injury (SCI) induces lasting decreases in Ang-1 levels, underlying endothelial barrier disruption, but the expression of Ang-2 in spinal cord injury has not been studied. We characterized Ang-2 after SCI using a clinically relevant rat model of contusion SCI. We found that SCI induces marked and persistent upregulation of Ang-2 (up to 10 weeks after SCI), which does not reflect well-characterized temporal profile of the blood-spinal cord barrier (BSCB) breakdown after SCI, and thus suggests other role(s) for Ang-2 in injured spinal cords. Furthermore, we also found that higher Ang-2 levels were associated with more successful locomotor recovery after SCI, both in SCI rats with markedly better spontaneous motor recovery and in SCI rats receiving a neuroprotective pharmacological intervention (amiloride), suggesting a beneficial role for Ang-2 in injured spinal cords. Immunocytochemical analyses revealed that Ang-2 was not induced in endothelial cells, but in perivascular and non-vascular cells labeled with glial fibrillary acidic protein (GFAP) or with chondroitin sulfate proteoglycan (NG2). Therefore, it is unlikely that induction of Ang-2 contributes to vascular dysfunction underlying functional impairment after SCI, but rather that it contributes to the beneficial pro-angiogenic and/or gliogenic processes underlying recovery processes after SCI. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22020092      PMCID: PMC3285476          DOI: 10.1016/j.neuroscience.2011.09.058

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  83 in total

Review 1.  Defining glial cells during CNS development.

Authors:  S C Zhang
Journal:  Nat Rev Neurosci       Date:  2001-11       Impact factor: 34.870

2.  Correlation of VEGF and angiopoietin expression with disruption of blood-brain barrier and angiogenesis after focal cerebral ischemia.

Authors:  Zheng Gang Zhang; Li Zhang; Wayne Tsang; Hamid Soltanian-Zadeh; Daniel Morris; Ruilan Zhang; Anton Goussev; Cecylia Powers; Thomas Yeich; Michael Chopp
Journal:  J Cereb Blood Flow Metab       Date:  2002-04       Impact factor: 6.200

3.  VEGF-induced BBB permeability is associated with an MMP-9 activity increase in cerebral ischemia: both effects decreased by Ang-1.

Authors:  Samuel Valable; Joan Montaner; Anita Bellail; Vincent Berezowski; Julien Brillault; Romeo Cecchelli; Didier Divoux; Eric T Mackenzie; Myriam Bernaudin; Simon Roussel; Edwige Petit
Journal:  J Cereb Blood Flow Metab       Date:  2005-11       Impact factor: 6.200

4.  Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention.

Authors:  Hoong Sern Lim; Andrew D Blann; Aun Yeong Chong; Bethan Freestone; Gregory Y H Lip
Journal:  Diabetes Care       Date:  2004-12       Impact factor: 19.112

5.  Gene expression profiling of experimental traumatic spinal cord injury as a function of distance from impact site and injury severity.

Authors:  Andrea De Biase; Susan M Knoblach; Simone Di Giovanni; Chenguang Fan; Annamaria Molon; Eric P Hoffman; Alan I Faden
Journal:  Physiol Genomics       Date:  2005-06-07       Impact factor: 3.107

6.  Oxygen tension regulates the maturation of the blood-brain barrier.

Authors:  Hyun Seok Song; Myung Jin Son; You Mie Lee; Woo Jean Kim; Sae-Won Lee; Chul Woo Kim; Kyu-Won Kim
Journal:  Biochem Biophys Res Commun       Date:  2002-01-11       Impact factor: 3.575

7.  Expression and purification of recombinant human angiopoietin-2 produced in Chinese hamster ovary cells.

Authors:  Su-Jeong Hwang; Han Ho Choi; Kyung-Tae Kim; Hyo Jeong Hong; Gou Young Koh; Gyun Min Lee
Journal:  Protein Expr Purif       Date:  2005-02       Impact factor: 1.650

Review 8.  Vascular endothelial growth factor and angiopoietins in neurovascular regeneration and protection following stroke.

Authors:  Tania M Hansen; Andrew J Moss; Nicholas P J Brindle
Journal:  Curr Neurovasc Res       Date:  2008-11       Impact factor: 1.990

Review 9.  Coordinated network functioning in the spinal cord: an evolutionary perspective.

Authors:  Mélanie Falgairolle; Mathieu de Seze; Laurent Juvin; Didier Morin; Jean-René Cazalets
Journal:  J Physiol Paris       Date:  2007-06-07

Review 10.  Angiopoietins in tumours: the angiogenic switch.

Authors:  Catherine R Tait; Pamela F Jones
Journal:  J Pathol       Date:  2004-09       Impact factor: 7.996

View more
  11 in total

1.  Omega-3 polyunsaturated fatty acids enhance cerebral angiogenesis and provide long-term protection after stroke.

Authors:  Jiayin Wang; Yejie Shi; Lili Zhang; Feng Zhang; Xiaoming Hu; Wenting Zhang; Rehana K Leak; Yanqin Gao; Ling Chen; Jun Chen
Journal:  Neurobiol Dis       Date:  2014-04-29       Impact factor: 5.996

2.  The cancer drug tamoxifen: a potential therapeutic treatment for spinal cord injury.

Authors:  Jutatip Guptarak; John E Wiktorowicz; Rovshan G Sadygov; Dragoslava Zivadinovic; Adriana A Paulucci-Holthauzen; Leoncio Vergara; Olivera Nesic
Journal:  J Neurotrauma       Date:  2013-12-11       Impact factor: 5.269

Review 3.  Propitious Therapeutic Modulators to Prevent Blood-Spinal Cord Barrier Disruption in Spinal Cord Injury.

Authors:  Hemant Kumar; Alexander E Ropper; Soo-Hong Lee; Inbo Han
Journal:  Mol Neurobiol       Date:  2016-05-18       Impact factor: 5.590

4.  Evidence for proangiogenic cellular and humoral systemic response in patients with acute onset of spinal cord injury.

Authors:  Edyta Paczkowska; Dorota Rogińska; Ewa Pius-Sadowska; Alina Jurewicz; Katarzyna Piecyk; Krzysztof Safranow; Violetta Dziedziejko; Ryszard Grzegrzółka; Andrzej Bohatyrewicz; Bogusław Machaliński
Journal:  J Spinal Cord Med       Date:  2014-06-26       Impact factor: 1.985

5.  An enriched environment reduces chronic stress-induced visceral pain through modulating microglial activity in the central nucleus of the amygdala.

Authors:  Tian Yuan; Albert Orock; Beverley Greenwood-VanMeerveld
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2021-12-08       Impact factor: 4.052

Review 6.  The Role of Biomaterials as Angiogenic Modulators of Spinal Cord Injury: Mimetics of the Spinal Cord, Cell and Angiogenic Factor Delivery Agents.

Authors:  Luís A Rocha; Rui A Sousa; David A Learmonth; António J Salgado
Journal:  Front Pharmacol       Date:  2018-02-27       Impact factor: 5.810

7.  Correlation between the Charlson comorbidity index and skeletal muscle mass/physical performance in hospitalized older people potentially suffering from sarcopenia.

Authors:  Ge Gong; Wenhui Wan; Xinghu Zhang; Yu Liu; Xinhui Liu; Jian Yin
Journal:  BMC Geriatr       Date:  2019-12-23       Impact factor: 3.921

8.  Decreased angiogenesis as a possible pathomechanism in cervical degenerative myelopathy.

Authors:  L O Brandenburg; C A Mueller; Christian Blume; M F Geiger; M Müller; H Clusmann; V Mainz; J Kalder
Journal:  Sci Rep       Date:  2021-01-28       Impact factor: 4.379

9.  Intravenous Injections of Human Mesenchymal Stromal Cells Modulated the Redox State in a Rat Model of Radiation Myelopathy.

Authors:  Jing Zhang; Lian-Bing Li; Zhu Qiu; Hong-Bo Ren; Jia-Yan Wu; Tao Wang; Zhong-Hui Bao; Ji-Fan Yang; Ke Zheng; Shao-Lin Li; Li Wei; Hua You
Journal:  Evid Based Complement Alternat Med       Date:  2015-08-23       Impact factor: 2.629

10.  Neutrophil elastase inhibition effectively rescued angiopoietin-1 decrease and inhibits glial scar after spinal cord injury.

Authors:  Hemant Kumar; Hyemin Choi; Min-Jae Jo; Hari Prasad Joshi; Manjunatha Muttigi; Dario Bonanomi; Sung Bum Kim; Eunmi Ban; Aeri Kim; Soo-Hong Lee; Kyoung-Tae Kim; Seil Sohn; Xiang Zeng; Inbo Han
Journal:  Acta Neuropathol Commun       Date:  2018-08-07       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.